Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT05784688	TitleStudy of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors	Phase Phase 1, Phase 2	Date Added 2023-03-27	Location Texas, United States Washington, United States Korea, Republic of	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs TU2218 + Pembrolizumab	Tags MSS/ MMRp
NCT ID NCT05838768	TitleStudy of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.	Phase Phase 1	Date Added 2023-05-03	Location California, United States Massachusetts, United States New York, United States Texas, United States Belgium China France Germany Israel Italy Japan Korea, Republic of Norway Singapore Spain Sweden Taiwan United Kingdom	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs HRO761, Irinotecan	Tags MSI-H/ MMRd
NCT ID NCT05722327	TitlePhase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer	Phase Phase 1	Date Added 2023-02-10	Location Texas, United States	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs cetuximab, Irinotecan, MRTX849	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05733611	TitleRP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC	Phase Phase 2	Date Added 2023-02-17	Location	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs	Tags MSS/ MMRp
NCT ID NCT05684211	TitleA Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer	Phase Phase 2	Date Added 2023-01-13	Location China	Prior IO Allowed No	CRC-directed Yes	Status Not yet recruiting	Drugs Ametumumab	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04117087	TitlePooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer	Phase Phase 1	Date Added 2019-10-07	Location Maryland, United States	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Ipilimumab, Nivolumab, Opdivo, Yervoy	Tags MSS/ MMRp
NCT ID NCT04948034	TitleThe Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)	Phase Phase 2	Date Added 2021-07-01	Location China	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Fruquintinib, Tislelizumab	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04607421	TitleA Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (BREAKWATER)	Phase Phase 3	Date Added 2020-10-29	Location Arizona, United States California, United States Florida, United States Illinois, United States Louisiana, United States Minnesota, United States Missouri, United States Nebraska, United States New Jersey, United States New York, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Argentina Australia Belgium Brazil Bulgaria Canada China Czechia Denmark Finland Germany India Italy Japan Korea, Republic of Mexico Netherlands New Zealand Norway Poland Russian Federation Slovakia South Africa Spain Sweden Taiwan Ukraine United Kingdom	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs 5-FU, Bevacizumab, capecitabine, cetuximab, encorafenib, Irinotecan, Leucovorin, oxaliplatin	Tags MSS/ MMRp
NCT ID NCT02856425	TitleTrial Of Pembrolizumab And Nintedanib	Phase Phase 1	Date Added 2016-08-04	Location France	Prior IO Allowed No	CRC-directed No	Status Recruiting	Drugs Nintedanib, Pembrolizumab, Keytruda, Ofev, Vargatef	Tags MSS/ MMRp
NCT ID NCT04659382	TitleStudy to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer	Phase Phase 2	Date Added 2020-12-09	Location France	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Atezolizumab, Bevacizumab, TheraSphere, XELOX	Tags MSS/ MMRp

Showing 181 to 190 of 299 entries